ACCUMULATION OF 3-(PHENYLAMINO)ALANINE, A CONSTITUENT IN L-TRYPTOPHANPRODUCTS IMPLICATED IN EOSINOPHILIA-MYALGIA-SYNDROME, IN BLOOD AND ORGANS OF THE LEWIS RATS
J. Adachi et al., ACCUMULATION OF 3-(PHENYLAMINO)ALANINE, A CONSTITUENT IN L-TRYPTOPHANPRODUCTS IMPLICATED IN EOSINOPHILIA-MYALGIA-SYNDROME, IN BLOOD AND ORGANS OF THE LEWIS RATS, Archives of toxicology, 69(4), 1995, pp. 266-270
3-(Phenylamino)alanine (PAA), a newly discovered impurity in case-asso
ciated L-tryptophan tablets, has been investigated as a possible contr
ibuting factor in the etiology of eosinophilia-myalgia syndrome (EMS).
We have studied distribution and elimination of PAA in rats which wer
e administered a single 5 mg/kg dose of PAA by gastric gavage. PAA con
centrations in blood, brain, kidney and liver were measured by high-pe
rformance liquid chromatography (HPLC) with electrochemical detection.
The concentration of PAA in each tissue reached a maximum at 5 h, and
then gradually declined. A high level of PAA still remained at 24 h,
indicating gradual elimination. The concentration of PAA in brain at 5
h was 2139 ng/g tissue, demonstrating passage through the blood-brain
barrier. Consecutive administration of PAA (5 mg/kg) for 4 days resul
ted in approximately double the concentration in all tissues. Chronic
treatment using PAA incorporated into food pellets for 6 weeks resulte
d in similar accumulations in each tissue, and following 12 days on a
PAA free diet, levels of this drug were still detectable in all tissue
s.